by Sermonix Pharmaceuticals | Oct 2, 2023 | News
More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapy About half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual...
by Sermonix Pharmaceuticals | Sep 5, 2023 | News
COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an...
by Sermonix Pharmaceuticals | Jun 30, 2023 | News
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE...
by Sermonix Pharmaceuticals | Jun 26, 2023 | News
Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patients The company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June 26, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Jun 5, 2023 | News
CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster...
by Sermonix Pharmaceuticals | May 26, 2023 | News
COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today shared...
Recent Comments